Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(3 sites)

China

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guanzhou, Guangdong

Zhong shan people's hospital, Zhongshan, Guangdong

Huazhong University of Science and Technology Union Hospital (Nanshan Hospital), Shenzhen, Nanshan